O212: Simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in HCV genotype 1-infected patients: the Phase III ATTAIN study
2014 ◽
Vol 146
(5)
◽
pp. S-977
Tarik Asselah
◽
Donald M. Jensen
◽
Graham Foster
◽
Mark Sulkowski
◽
Denis Ouzan
◽
...
2014 ◽
Vol 146
(5)
◽
pp. S-976
Kristi Berger
◽
Christoph Sarrazin
◽
Peter Ferenci
◽
Donald M. Jensen
◽
Ira M. Jacobson
◽
...
2014 ◽
Vol 60
(1)
◽
pp. S457
I.M. Jacobson
◽
D.M. Jensen
◽
D. Dieterich
◽
C. Sarrazin
◽
G.R. Foster
◽
...
2014 ◽
Vol 60
(1)
◽
pp. S310-S311
T. Asselah
◽
D.M. Jensen
◽
G.R. Foster
◽
M.S. Sulkowski
◽
D. Ouzan
◽
...
2014 ◽
Vol 146
(5)
◽
pp. S-976
Cristina Tural
◽
Jürgen K. Rockstroh
◽
Mark Nelson
◽
Sanjay Bhagani
◽
Patrick Ingiliz
◽
...
2014 ◽
Vol 60
(1)
◽
pp. S469
C. Tural
◽
J.K. Rockstroh
◽
M. Nelson
◽
S. Bhagani
◽
P. Ingiliz
◽
...
2014 ◽
Vol 146
(5)
◽
pp. S-976
Ira M. Jacobson
◽
Donald M. Jensen
◽
Douglas T. Dieterich
◽
Christoph Sarrazin
◽
Graham Foster
◽
...
2013 ◽
Vol 58
◽
pp. S574
◽
I. Jacobson
◽
G.J. Dore
◽
G.R. Foster
◽
M.W. Fried
◽
M. Radu
◽
...
2016 ◽
Vol 15
(3)
◽
pp. 333-349
◽
Donald M. Jensen
◽
Tarik Asselah
◽
Douglas Dieterich
◽
Graham R. Foster
◽
Mark S. Sulkowski
◽
...
2013 ◽
Vol 144
(5)
◽
pp. S-374
◽
Ira M. Jacobson
◽
Gregory J. Dore
◽
Graham Foster
◽
Michael W. Fried
◽
Monica N. Radu
◽
...
Close
Export Citation Format
Close
Share Document
Close